Latest

TORL BioTherapeutics Presents Preliminary Safety and Efficacy Data of Ixotatug Vedotin (TORL-1-23) in Combination with Bevacizumab in Recurrent Ovarian Cancer at ESMO Gynaecological Cancers Congress 2026

TORL BioTherapeutics Presents Preliminary Safety and Efficacy Data of Ixotatug Vedotin (TORL-1-23) in Combination with Bevacizumab in Recurrent Ovarian Cancer at ESMO Gynaecological Cancers Congress 2026

Objective response rate across all 29 participants was 32.1%; Favorable disease control rate (92.9%) across all participants was observed Data suggest that the combination of Ixo-V and bevacizumab may expand therapeutic options for Claudin 6-positive patients in both the platinum-resistant and platinum-sensitive settings Pivotal
TORL Biotherapeutics LLC
Epson Robots to Showcase SafeSense Technology, High-Performance, Compact SCARA and 6-Axis Solutions and First Look at Epson Collaborative Robot at Automate 2026

Epson Robots to Showcase SafeSense Technology, High-Performance, Compact SCARA and 6-Axis Solutions and First Look at Epson Collaborative Robot at Automate 2026

Epson Interactive Demos Highlight Breadth of Flexible, Cost-Effective Automation Solutions LOS ALAMITOS, Calif., June 18, 2026 /PRNewswire/ -- Epson Robots, the #1 SCARA robot manufacturer in the world, will be showcasing its automation portfolio, including SafeSense™ technology, high-performance SCARA and 6-Axis solutions and a preview of its upcoming
Epson America